| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
TNGX
Tango Therapeutics
|
Jun 08, 2026 | BUY |
Strong Buy
+24.3% avg upside
14 analysts
|
$36.00
28.79% Upside
|
+4.4% |
|
QTTB
Q32 Bio
|
May 22, 2026 | BUY |
Strong Buy
+345.2% avg upside
24 analysts
|
$14.00
17.69% Upside
|
· |
|
UPB
Upstream Bio, Inc.
|
May 14, 2026 | BUY |
Strong Buy
+514.9% avg upside
9 analysts
|
$50.00
700.00% Upside
|
-26.6% |
|
AVTX
Avalo Therapeutics
|
May 14, 2026 | BUY |
Strong Buy
+265.1% avg upside
19 analysts
|
$45.00
206.07% Upside
|
-14.0% |
|
ERAS
Erasca
|
May 12, 2026 | BUY |
Strong Buy
+39.0% avg upside
14 analysts
|
$26.00
90.23% Upside
|
+34.7% |
|
STRO
Sutro Biopharma
|
Apr 30, 2026 | BUY |
Strong Buy
+31.6% avg upside
20 analysts
|
$50.00
68.71% Upside
|
-21.3% |
|
RVMD
Revolution Medicines
|
Apr 24, 2026 | BUY |
Strong Buy
-12.3% avg upside
32 analysts
|
$185.00
13.50% Upside
|
+16.6% |
|
CLYM
Climb Bio
|
Apr 15, 2026 | BUY |
Strong Buy
+57.9% avg upside
18 analysts
|
$18.00
57.23% Upside
|
+24.9% |
|
SYRE
Spyre Therapeutics
|
Apr 14, 2026 | BUY |
Strong Buy
-15.4% avg upside
23 analysts
|
$84.00
4.87% Downside
|
+30.6% |
|
APGE
Apogee Therapeutics
|
Mar 30, 2026 | BUY |
Strong Buy
+28.5% avg upside
19 analysts
|
$110.00
21.76% Upside
|
+12.3% |
|
EIKN
Eikon Therapeutics, Inc.
|
Mar 02, 2026 | BUY |
Strong Buy
+147.2% avg upside
5 analysts
|
$26.00
170.65% Upside
|
· |
|
NRIX
Nurix Therapeutics
|
Jan 29, 2026 | BUY |
Strong Buy
+75.6% avg upside
26 analysts
|
$30.00
70.91% Upside
|
-0.0% |
|
KYMR
Kymera Therapeutics
|
Jan 29, 2026 | BUY |
Strong Buy
+8.9% avg upside
36 analysts
|
— | +21.6% |
|
CLDX
Celldex
|
Jan 09, 2026 | BUY |
Strong Buy
+20.6% avg upside
28 analysts
|
$48.00
48.01% Upside
|
+18.2% |
|
BCAX
Bicara Therapeutics Inc.
|
Dec 18, 2025 | HOLD |
Strong Buy
+34.1% avg upside
14 analysts
|
$18.00
22.59% Downside
|
+29.9% |
|
CNTX
Context Therapeutics
|
Mar 21, 2025 | BUY |
Strong Buy
+873.3% avg upside
12 analysts
|
$4.50
612.13% Upside
|
+180.5% |
|
LENZ
LENZ Therapeutics
|
Mar 20, 2025 | BUY |
Buy
+284.0% avg upside
17 analysts
|
$38.00
517.86% Upside
|
-74.0% |
|
CTMX
CytomX Therapeutics
|
Mar 07, 2025 | BUY |
Strong Buy
+269.6% avg upside
21 analysts
|
$3.25
10.08% Upside
|
+352.6% |
|
HALO
Halozyme
|
Mar 06, 2025 | HOLD |
Strong Buy
-13.7% avg upside
20 analysts
|
$53.00
22.75% Downside
|
+14.0% |
|
IBRX
ImmunityBio
|
Mar 03, 2025 | HOLD |
Strong Buy
+52.6% avg upside
12 analysts
|
$4.25
42.34% Downside
|
+179.7% |
|
CRDF
Cardiff Oncology
|
Feb 28, 2025 | BUY |
Strong Buy
+732.8% avg upside
18 analysts
|
$10.00
726.53% Upside
|
-60.9% |
|
IOVA
Iovance Biotherapeutics
|
Feb 28, 2025 | HOLD |
Strong Buy
+225.8% avg upside
24 analysts
|
$6.00
53.40% Upside
|
-18.6% |
|
SDGR
Schrodinger
|
Feb 27, 2025 | BUY |
Strong Buy
+79.8% avg upside
14 analysts
|
$45.00
185.48% Upside
|
-35.1% |
|
GILD
Gilead Sciences
|
Feb 12, 2025 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
$110.00
11.15% Downside
|
+24.7% |
|
EXEL
Exelixis
|
Feb 12, 2025 | BUY |
Buy
-21.0% avg upside
33 analysts
|
$38.00
26.73% Downside
|
+62.0% |
|
CYPH
Cypherpunk Technologies
|
Jan 29, 2025 | BUY |
Buy
+1087.0% avg upside
9 analysts
|
$3.00
305.79% Upside
|
· |
|
KROS
Keros Therapeutics
|
Jan 17, 2025 | BUY |
Strong Buy
+139.0% avg upside
21 analysts
|
$15.00
40.82% Upside
|
-3.3% |
|
IMTX
Immatics
|
Nov 06, 2024 | BUY |
Strong Buy
+86.8% avg upside
15 analysts
|
$19.00
94.29% Upside
|
+18.3% |
|
BMEA
Biomea Fusion
|
Oct 31, 2024 | BUY |
Buy
+1037.0% avg upside
15 analysts
|
$19.00
1510.26% Upside
|
-84.4% |
|
BDTX
Black Diamond Therapeutics
|
Oct 08, 2024 | BUY |
Strong Buy
+984.3% avg upside
12 analysts
|
$15.00
803.68% Upside
|
-22.6% |
|
NBP
NovaBridge Biosciences
|
Sep 16, 2024 | BUY |
Strong Buy
+1309.7% avg upside
14 analysts
|
$8.00
433.43% Upside
|
· |
|
ACRV
Acrivon Therapeutics, Inc.
|
Sep 16, 2024 | BUY |
Strong Buy
+817.2% avg upside
13 analysts
|
$30.00
1810.89% Upside
|
-78.5% |
|
WHWK
Whitehawk Therapeutics
|
Aug 27, 2024 | HOLD |
Buy
+201.4% avg upside
12 analysts
|
$1.75
60.40% Downside
|
+151.2% |
|
BOLD
Boundless Bio Inc.
|
Apr 22, 2024 | BUY |
Buy
+529.4% avg upside
11 analysts
|
$20.00
1298.67% Upside
|
-84.5% |
|
OCUL
Ocular Therapeutix
|
Apr 08, 2024 | BUY |
Strong Buy
+160.4% avg upside
21 analysts
|
$15.00
59.11% Upside
|
+5.4% |
|
CPRX
Catalyst Pharma
|
Mar 14, 2024 | BUY |
Strong Buy
-17.0% avg upside
15 analysts
|
$26.00
17.07% Downside
|
+43.5% |
|
CNTB
Connect Biopharma Holdings
|
Sep 14, 2022 | HOLD |
Strong Buy
+226.3% avg upside
11 analysts
|
$1.75
12.57% Downside
|
-10.9% |
|
MRKR
Marker Therapeutics
|
May 31, 2022 | BUY |
Strong Buy
+994.4% avg upside
9 analysts
|
$15.00
1027.91% Upside
|
+29.0% |
|
NGNE
Neurogene
|
May 31, 2022 | BUY |
Strong Buy
+55.5% avg upside
23 analysts
|
$6.00
80.91% Downside
|
+88.0% |
|
FTH
Faeth Therapeutics
|
May 12, 2022 | BUY |
Strong Buy
+108.4% avg upside
11 analysts
|
$4.00
77.57% Downside
|
· |
|
FIGS
FIGS
|
Mar 09, 2022 | BUY |
Buy
+45.6% avg upside
17 analysts
|
$36.00
192.46% Upside
|
-67.5% |
|
NCNA
Nucana
|
Aug 21, 2020 | BUY |
Buy
+559.7% avg upside
9 analysts
|
$17.00
790.05% Upside
|
-71.5% |
|
XBIT
XBiotech
|
Apr 07, 2020 | BUY |
Buy
+506.0% avg upside
2 analysts
|
$18.00
679.13% Upside
|
-15.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.